BioNTech

Pfizer reported its fourth-quarter and full-year results on Tuesday

Pfizer yesterday applied to the US Medicines Agency to allow the emergency use of the vaccine produced by the company to children aged 6 months to 4 years, AFP and Reuters reported.

Turkey has started to give the locally developed inactivated vaccine, Turkovac, as a booster shot to those who have already received two doses of the Pfizer/BioNTech mRNA jab.

Kosovo will not withdraw its decision to demand three COVID-19 vaccine doses or two doses together with a negative PCR test for foreigners entering the country or for citizens who have spent more than 12 hours abroad, despite complaints from people and businesses in the region who frequently pass the border.

According to studies by the Centers for Disease Control and Prevention in the United States, vaccine protection has dropped to 94% during the Delta variant and to 82% during Omicron. These are the first 3 major studies looking at the extent to which vaccines protect against Omicron.

Bulgaria will donate 258,570 doses of Comirnaty vaccine from Pfizer/Biontech to Bosnia and Herzegovina, the government decided.

Turkey will give a dose of a locally developed COVID-19 vaccine, Turkovac, to those who have already received two doses of the Pfizer/BioNTech jab, Health Minister Fahrettin Koca has said.

Professor of Health Policy at LSE Elias Mosialos wrote on the approval of the coronavirus vaccine for children and specifically for the ages of 5 to 11 years, the , by posting an extended message on his personal Facebook account.

Prof. Mosialos refers to the clinical trials that were carried out until the licensing of vaccines for children aged 5 to 11 years.

Three doses of the Pfizer-BioNTech coronavirus vaccine appear effective against the Omicron variant, a lab test indicated - encouraging news, even as Denmark and Britain announced new restrictions to stem surging caseloads.

The coronavirus variant Omicron may partially evade protection from two doses of vaccine produced by Pfizer Inc. and partner BioNTech, Alex Seagal, head of research at a South African laboratory, told Reuters on Tuesday.